MOSCOW: Russia on Saturday approved a third coronavirus vaccine for domestic use, Prime Minister Mikhail Mishustin said on state TV, though large-scale clinical trials of the shot, labelled CoviVac and produced by the Chumakov Centre, have yet to begin.
Russia has already approved two COVID-19 vaccines, including the Sputnik V shot, developed by Moscow's Gamaleya Institute, following a similar approach of granting approval before seeing any late-stage trial results.
The preemptive approvals had raised concerns among some scientists in the West, but inoculations with those first two shots began on a mass scale in Russia only after trials were concluded and showed success.
Sputnik V was approved in August and late-stage trials began in September. Mass vaccination was launched in December, after preliminary trial results showed the vaccine to be 91.4% effective.
Since then, more than two million Russians have been vaccinated with at least the first dose of Sputnik V, Health Minister Mikhail Murashko said on Feb. 10.
Rollout of a second vaccine, developed by the Vector Institute in Novosibirsk, is beginning.
"Today, Russia is the only country to have already three vaccines against COVID-19," Prime Minister Mishustin said.
The Chumakov Centre, founded in 1955 in St Petersburg by Mikhail Chumakov, is known for its work with U.S. scientist Albert Sabin at the height of the Cold War, which led to the production of the widely-used polio vaccine.
DIFFERENT TYPE OF VACCINE
Unlike the Sputnik V vaccine, which uses a modified harmless cold virus that tricks the body into producing antigens to help the immune system prepare for a coronavirus infection, the CoviVac vaccine is a "whole-virion" vaccine.
This means it is made of a coronavirus that has been inactivated, or stripped of its ability to replicate.
"The vaccine we have developed... reflects the whole history of Russian, as well as global, vaccine science," the Chumakov Centre's director, Aidar Ishmukhametov, said on Saturday.
The advantage, according to virologist Alexander Chepurnov, cited by outlet Lenta.Ru, is that CoviVac includes all elements of the virus, creating a broader immune response that is likely to protect against any variants.
However, testing Russia's COVID-19 shots against SARS-CoV-2 variants that have emerged in the UK, South Africa and elsewhere is in its early stages. President Vladimir Putin on Monday ordered a review of Russia's COVID-19 vaccines to be presented by March 15 assessing their ability to protect against the new variants.
RESULTS SO FAR
Globally, one other major vaccine candidate - India's COVAXIN by Bharat Biotech - uses the "whole-virion" approach.
India's drug regulator has touted the shot's ability to act against the whole body of a virus instead of just its "spike-protein" tip, potentially making it more effective in case of mutations.
The CoviVac shot is given in two doses, 14 days apart. It is transported and stored at normal fridge temperatures, of 2 to 8 degrees Celsius (35.6 to 46.4 Fahrenheit), Deputy Prime Minister Tatiana Golikova said in a government briefing in January.
The shot has already been tested for safety on 200 people aged between 18 and 60, Ishmukhametov told the state-run Vesti-24 news channel in late January.
This early-stage trial began on Sept. 21 last year, according to the state clinical trials register. It showed no side-effects, including no rise in temperature, Ishmukhametov said.
Mid-stage trials to test volunteers' immune responses were ongoing, he said at the time.
Only a placebo-controlled, large-scale trial could ascertain effectiveness, he added. This is due to begin now that the go-ahead has been granted.
The first 120,000 doses, however, will be produced and released to the national inoculation programme in March, Mishustin said.
Then, the Chumakov Centre will produce around half a million doses per month on its platforms, Ishmukhametov said on Saturday.
Deputy Prime Minister Golikova also announced on Saturday that Russia will produce 88 million vaccine doses in the first half of this year, including 83 million Sputnik V doses.
Reuters
Sat Feb 20 2021
Russian Prime Minister Mikhail Mishustin chairs a meeting with senior executives of the Central Office of Russian Government in Moscow, Russia, Jan 19, 2021. REUTERSpic
US military plane deporting Indian immigrants lands in India
The Trump administration has increasingly turned to the military to help carry out its immigration agenda.
Trump's Gaza plan for 'Riviera of the Middle East' triggers international condemnation
Countries from Russia, China, Spain, Ireland and the UK say they continue to support the two-state solution.
US Postal Service suspends inbound parcels from China, Hong Kong
Trump's crackdown on de minimis would make the products sold by the likes of Shein and Temu more expensive.
US plan to take over Gaza: Malaysia's stance on Palestine unchanged - PM
Datuk Seri Anwar Ibrahim says Malaysia's stance remains the same as that of other Islamic countries.
US freezes funding for security mission tackling Haiti's gangs
More than $13 million in US funding for an international security force helping fight armed gangs in Haiti has been frozen, the UN says.
Over 40,000 civil servants at high risk of mental health issues - Zaliha
A total of 44,901 civil servants were screened under Public Service Psychological Health Digital Profiling System, says Dr Zaliha Mustafa.
India's Modi takes 'holy dips' at Maha Kumbh, week after stampede killed dozens
Security personnel stood in the water nearby while thousands of people crowded the banks to watch the prime minister perform the rituals.
Philippine Congress endorses impeachment complaint against vice president
Vice President Sara Duterte would be the Philippines' second most senior official to face removal from office.
What is a sovereign wealth fund?
Sovereign wealth funds are investment vehicles owned by countries.
[COLUMNIST] Rising above Trump tariffs: How a resilient global economy outlasts US protectionism
The current alarm over Trumps tariff threats overlooks a key point: global markets are resilient and adaptable.
Khazanah reports RM5.1 billion operating profit for 2024
Khazanah records RM103.6 billion NAV in 2024, driven by strong domestic investments and strategic growth.
Washington, DC officials identify 66 of 67 victims of midair collision
Work continues by the US Army Corps of Engineers to remove the airplane wreckage from the Potomac River.
Government to further strengthen ASEAN's readiness in finalising DEFA
Malaysia is focusing on two main approaches to facilitate the DEFA negotiation, says Liew Chin Tong.
Trade war will not hinder Malaysia’s GDP growth for 2025 - Rafizi
The finance ministry has projected Malaysia's GDP to grow between 4.5 and 5.5 per cent in 2025.
Trump administration considers adding Shein, Temu to 'forced labor' list, Semafor reports
The move comes after China imposes targeted tariffs on US imports and warnings of possible sanctions against firms like Google.
Thailand to cut power to Myanmar border areas linked to scam centres
Evidence shows transnational crime syndicates in Myanmar's Tachileik, Myawaddy, Payathonzu, that are possible power cut targets.
Trump reimposes 'maximum pressure' on Iran, aims to drive oil exports to zero
Trump signs the presidential memorandum reimposing Washington's tough policy on Iran that was practiced throughout his first term.
FACTBOX: Trump proposes US takeover of Gaza
Here are some remarks that US President Donald Trump made and questions that he answered during a press conference.
Singapore passes law against foreign interference in race-based organisations
Under the Racial Harmony Bill, race-based groups must disclose foreign and anonymous donations, affiliations, and leadership.
Malaysia, Uzbekistan agree to elevate ties to strategic partnership
Malaysia and Uzbekistan noted active cooperation on key issues within international bodies, especially the UN and OIC.